Pancreatic Cancer

The overall survival benefit seen with DOC1021 in a phase 1 trial of glioblastoma support the fast track status decision for the agent.

More than half of the patients who received mitazalimab plus chemotherapy experienced an unconfirmed objective response in the phase 2 OPTIMIZE-1 study.

Longer survival rates were experienced by patients receiving chemotherapy both before and after surgery vs only after surgery.

Data from a phase 1 trial may support the utility of IBI343 for patients with advanced pancreatic ductal adenocarcinoma.

Data from the phase 1/2 eNRGy trial support the biologics license application for zenocutuzumab in NRG1-positive NSCLC and PDAC.

Safety findings highlight no severe adverse effects or dose-limiting toxicities with the rintatolimod combination in late-stage pancreatic cancer.

The liquid biopsy combining miRNA and CA19-9 had the best validation rates for detecting pancreatic ductal adenocarcinoma.

Higher CA19-9 levels appear to correlate with increased recurrence and mortality for specific patients with pancreatic cancer who undergo surgical resection.

Investigators are currently evaluating treatment with IMM-1-104 in pancreatic cancer and other disease types associated with the RAS pathway as part of a phase 1/2a study.

A retrospective cohort study from the Trans-Atlantic Pancreatic Surgery Consortium determined a sustained OS rate with modified FOLFIRINIX in patients with pancreatic ductal adenocarcinoma.

Patients with metastatic pancreatic ductal adenocarcinoma may now receive irinotecan liposome in combination with 5-fluorouracil/leucovorin and oxaliplatin in the first-line setting, which has been approved by the FDA.

Investigators of the AMPLIFY-201 trial hypothesized that ELI-002 2P may induce the expansion of functional tumor-directed KRAS-mutated specific T cells following tumor resection.

Treatment with NT-I7 may boost the immune system and enhance antitumor activity in patients with pancreatic cancer and other solid tumors.

Starting April 1, 2024, Diane Simeone will be the new director of UCSD Moores Cancer Center.

Data from a phase 2 trial support the potential survival benefit of CAN-2409 plus prodrug for patients with borderline resectable pancreatic ductal adenocarcinoma.

Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.

Medical oncologists provide insights on the evolving molecular testing practices for NRG1 fusions.

Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, define NRG1 fusions and outline their incidence and effect on prognosis.

Developers plan to assess onvansertib plus standard of care as a frontline treatment for patients with metastatic pancreatic ductal adenocarcinoma in an investigator-initiated trial.

LSAM-PTX plus standard of care appears efficacious in a small population of patients with locally advanced pancreatic cancer.

Clearance of an automated immunoassay allows practices to measure chromogranin A concentration in human serum, thereby tracking disease progression in those with gastroenteropancreatic neuroendocrine tumors.

The safety profile of cabozantinib as a treatment for patients with advanced pancreatic neuroendocrine tumors in the phase 3 CABINET trial is comparable with previous reports of the agent.

The investigational drug MAb-AR20.5 is the first monoclonal antibody targeting MUC1 to receive orphan drug designation from the FDA as a treatment for pancreatic cancer.

Elraglusib is currently under evaluation as a treatment for patients with several types of advanced cancers as part of the phase 1/2 1801 trial.

Data from the phase 1/2 eNRGy trial assessing zenocutuzumab in patients with NRG1 fusion–positive cancer support the FDA’s breakthrough therapy designation for the agent as a treatment for pancreatic cancer.

The oncolytic adenovirus VCN-01 is under investigation as a treatment for metastatic pancreatic ductal adenocarcinoma in the phase 2b VIRAGE trial.

Investigators expect to have a readout of topline data from the phase 2 OPTIMIZE-1 trial evaluating mitazalimab plus chemotherapy in metastatic pancreatic ductal adenocarcinoma in early 2024.

The FDA sets a Prescription Drug User Fee Act date of February 13, 2024 for NALIRIFOX as a treatment for patients with metastatic pancreatic ductal adenocarcinoma.

Findings from the phase 3 NAPOLI 3 trial support NALIRIFOX as a novel reference regimen for first-line metastatic pancreatic ductal adenocarcinoma.